Abstract
Epigenetic alterations have been associated with several human diseases including Alzheimers disease (AD). AD is a complex neurodegenerative disease characterized by a progressive decline in cognitive functions, neuronal cell loss and by the presence of β amyloid (Aβ) plaques and neurofibrillary tangles (NFTs) in the cortex. Mutations in specific genes have been identified but can only explain a small percentage of the AD cases. The origins of the sporadic cases of AD are still not known but there is evidence for a role of epigenetics in the etiology of the disease. In this review we focus on discussing the roles of DNA methylation and hydroxymethylation in the development and potential treatment of AD. We discuss papers showing that there are alterations in methylated cytosine (5mC) levels in AD and also highlight the potential role of hydroxylated methylcytosine (5hmC) in the epigenetic regulation of brain gene expression and perhaps in AD. We discuss the potential influence of environmental factors, working through epigenetic mechanisms, on increasing the risk of developing AD and their potential in treating this major neurodegenerative disorder.
Keywords: Alzheimer's disease, DNA methylation, epigenetics, 5-methylcytosine, 5-hydroxymethylcytosine, environment, pronucleus, aging, neurons, oxidative stress
Current Pharmaceutical Design
Title: Epigenetics in Alzheimers Disease: a Focus on DNA Modifications
Volume: 17 Issue: 31
Author(s): Natacha Coppieters and Mike Dragunow
Affiliation:
Keywords: Alzheimer's disease, DNA methylation, epigenetics, 5-methylcytosine, 5-hydroxymethylcytosine, environment, pronucleus, aging, neurons, oxidative stress
Abstract: Epigenetic alterations have been associated with several human diseases including Alzheimers disease (AD). AD is a complex neurodegenerative disease characterized by a progressive decline in cognitive functions, neuronal cell loss and by the presence of β amyloid (Aβ) plaques and neurofibrillary tangles (NFTs) in the cortex. Mutations in specific genes have been identified but can only explain a small percentage of the AD cases. The origins of the sporadic cases of AD are still not known but there is evidence for a role of epigenetics in the etiology of the disease. In this review we focus on discussing the roles of DNA methylation and hydroxymethylation in the development and potential treatment of AD. We discuss papers showing that there are alterations in methylated cytosine (5mC) levels in AD and also highlight the potential role of hydroxylated methylcytosine (5hmC) in the epigenetic regulation of brain gene expression and perhaps in AD. We discuss the potential influence of environmental factors, working through epigenetic mechanisms, on increasing the risk of developing AD and their potential in treating this major neurodegenerative disorder.
Export Options
About this article
Cite this article as:
Coppieters Natacha and Dragunow Mike, Epigenetics in Alzheimers Disease: a Focus on DNA Modifications, Current Pharmaceutical Design 2011; 17 (31) . https://dx.doi.org/10.2174/138161211798072544
DOI https://dx.doi.org/10.2174/138161211798072544 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
NMN/NaMN Adenylyltransferase (NMNAT) and NAD Kinase (NADK) Inhibitors: Chemistry and Potential Therapeutic Applications
Current Medicinal Chemistry The Endocannabinoid System and Huntingtons Disease
Current Drug Targets - CNS & Neurological Disorders Renin-Angiotensin-Aldosterone System: A Current Drug Target for the Management of Neuropathic Pain
Current Drug Targets Oxidative DNA Damage and Oxidant/Anti-Oxidant Enzymatic Systems in Carcinogenesis and Cancer Progression
Current Enzyme Inhibition Editorial (Thematic Issue: Neuroprotective Effects of Li - It is Elementary)
Current Alzheimer Research ROCK in CNS: Different Roles of Isoforms and Therapeutic Target for Neurodegenerative Disorders
Current Drug Targets From Chemical Drug to Immunotherapy: New Approaches for the Treatment of Prion Diseases
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents New Proposals for Treatment Sporadic Alzheimers Disease
Central Nervous System Agents in Medicinal Chemistry Editorial (Thematic Issue: New Approaches to the Treatment of Alzheimer's Disease)
Current Topics in Medicinal Chemistry Axotomy Leads to Reduced Calcium Increase and Earlier Termination of CCL2 Release in Spinal Motoneurons with Upregulated Parvalbumin Followed by Decreased Neighboring Microglial Activation
CNS & Neurological Disorders - Drug Targets In Vitro Modeling of the Blood-Brain Barrier: Simplicity Versus Complexity
Current Pharmaceutical Design Astrocytes and Inflammasome: A Possible Crosstalk in Neurological Diseases
Current Medicinal Chemistry Anti-Inflammatory Drugs in Psychiatry
Inflammation & Allergy - Drug Targets (Discontinued) Classical Neurotransmitters and Neuropeptides Involved in Parkinson's Disease: Focus on Anti-Parkinsonian Drugs
Current Drug Therapy Alzheimer's Disease: A Review from the Pathophysiology to Diagnosis, New Perspectives for Pharmacological Treatment
Current Medicinal Chemistry Editorial: Current and Emerging Therapeutics in AD
Current Alzheimer Research Stem Cells: In Sickness and in Health
Current Stem Cell Research & Therapy The Role of Melatonin in Multiple Sclerosis, Huntington's Disease and Cerebral Ischemia
CNS & Neurological Disorders - Drug Targets The Interface Between Alzheimers Disease, Normal Aging, and Related Disorders
Current Aging Science Relevant Modulation by Ferrous Ions of N-Methyl-D-Aspartate Receptors in Ischemic Brain Injuries
Current Neurovascular Research